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Background:	Human	Immunodeficiency	Virus	(HIV)	 is	characterized	by	high	rates	of	genetic	variability	 in vivo	 that	
could	affect	the	performance	of	the	HIV	antibody-based	detection	kits.		
Objective: This	 study	 aimed	 at	 developing	 immunoassays	 for	 HIV	 based	 on	 Consensus env	 gp41	 Immunodominant	
region	(IDR)	from	HIV	infections	in	Kenya.		
Methods:	HIV	RNA	was	extracted	from	91	samples	collected	from	5	regional	blood	transfusion	centers	in	Kenya.	The	
RNA	was	reverse	transcribed,	sequenced	in	the	env	gp41-Immunodominant	Region	(IDR)	and	the	Consensus	sequence	
generated	used	to	synthesize	 corresponding	peptide.	The	 Global	HIV	envgp41-IDR	 Consensus	peptide	was	 obtained	
from	the	literature	and	also	synthesized.	The	two	peptides	were	used	to	separately	develop	HIV	immunoassays	based	
on	 Enzyme-linked	 Immunosorbent	 Assay	 (ELISA)	 and	 Lateral	 Flow	 Assay	 (LFA)	 platforms	 and	 the	 performance	 of	
developed	 assays	 was	 evaluated.	 The	 same	 HIV	 env	 gp41	 IDR	 peptides	 were	 used	 to	 develop	 ELISA-based	
immunoassays	for	determination	HIV	Incidence	/	Recency.	
Results: The	 study	 did	 not	 find	 significant	 difference	 between	 the	 performance	 of	 the	 immunoassays	 that	 were	
developed	with	Consensus env gp41-IDR	peptide	(Kenya)	and	those	developed	using	Consensus env gp41-IDR	peptide	
(Global).	However,	the	study	found	a	significant	difference	between	the	performance	of	HIV	ELISA	for	HIV	Incidence	
testing	 that	 was	 developed	 with	 Consensus envgp41-IDR	 peptide	 (Kenya)	 and	 that	 which	 was	 developed	 using	
Consensus envgp41-IDR	peptide	(Global)	with	the	former	displaying	superior	performance.	
Conclusions: The	 developed	 immunoassays	 demonstrated	 that	 both	 Consensus env gp41-IDR	 peptides	 (Kenya	 and	
Global)	 could	 be	 used	 to	 develop	 HIV	 immunoassays	 but	 Consensus env gp41-IDR	 peptide	 (Kenya)	 could	 be	 more	
suitable	for	development	of	HIV	Incidence	assays	in	Kenya.			
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1. Introduction 
HIV	infections	continue	to	be	a	great	menace	to	the	lives	
of	 many	 people	 globally	 with	 35	 million	 living	 with	
HIV/AIDS	 and	 more	 than	 3	 million	 new	 cases	 being	
reported	 each	 year	 (UNAIDS,	 2013).	 In	 Kenya,	 the	
overall	 HIV	 prevalence	 is	 6.0%	 with	 the	 prevalence	 of	
2.2%	 among	 young	 people	 (15-24yrs)	 and	 1.6	 million	
people	living	with	AIDS	(NASCOP,	2014).		
HIV	genome,	 with	 about	9749	nucleotides,	 encodes	 for	
three	 structural	 genes	 (pol, gag, and env)	 and	 six	
regulator	 genes	 (nef, vpu, vif, tat, rev and	 vpr).	 The	 env 
gene	 encodes	 for	 gp160	 that	 is	 enzymatically	 cleaved	
into	 two	 peptides,	 env gp120	 and	 env gp41.	 The	 env 
gp41	 peptide	 contains	 the	 Immunodominant	 Region	
(IDR)	 in	 the	 amino-terminal	 portion	 from	 which	 more	
than	 99%	 of	 HIV-1infected	 individuals	 produce	
antibodies	 directed	 to	 the	 region	 (Kartekayan	 et	 al,	
1998;	 Los	 Alamos,	 2015;	 Masciotra	 et	 al, 2000).	 HIV	 is	
known	to	exhibit	high	rates	of	genetic	variability	in vivo 
due	 to	 the	 poor	 proof-reading	 mechanisms	 during	
reverse	 transcription	 (that	 result	 in	 mutations	 and	
recombinations)	 and	 rapid	 viral	 turnover	 in	 patients	
with	 an	 active	 disease.	 These	 mutations	 and	
recombinations	have	resulted	in	evolution	of	HIV-1	into	
various	groups	("major"	group	M	that	constitutes	more	
than	90%	of	all	HIV-1,	the	"Outlier"	group	“O”,	N	and	P).	
Group	M	is	further	divided	into	nine	genetically	distinct	
subtypes	/	clades:	A,	B,	C,	D,	F,	 G,	H,	 J	and	K.	The	virus	
has	 also	 evolved	 into	 various	 Circulating	 Recombinant	
Forms	 (CRFs)	 and	 Unique	 Recombinant	 Forms	 (URFs).	
Majority	of	the	recombinants,	though,	do	not	survive	for	
long.	The	nucleotide	variations	within	the	env gene	are	
5	 to	 15%	 intra-clade	 and	 15	 to	 30%	 inter-clades	
(Leitner,	 1996;	 Korber	 et	 al, 1997;	 Quinones-Mateu	 et	
al, 1999;	Bobkov	et	al, 2004;	Plantier,	2009).	
Arising	from	the	diversity	within	the	env	gene	of	HIV-1,	
some	 studies	 have	 demonstrated	 that	 the	 performance	
of	various	HIV	immunoassays	have	been	affected	by	the	
prevailing	subtypes	of	HIV	infections	in	a	specific	region	
(Thorstensson	et	al, 1998; Wei	et	al, 2010;Kilembeet	al,	
2012).	A	study	by	Thorstensson	et	al (1998)	compared	
the	 performance	 of	 14	 commercially	 available	 HIV-1/2	
immunoassaysfrom	patient	sera	from	Tanzania,	Sweden	
and	 Guinea-Bissau	 and	 found	 that	 85.7%	 (n	 =	 12)	 of	
these	 kits	 identified	 correctly	 all	 HIV-1	 and	 HIV-2	
antibody	 positive	 sera	 and	 that	 one	 Tanzanian	 HIV-1	
antibody	positive	sample	was	not	detected	by	two	of	the	
ELISAs	 employing	 synthetic	 peptides.	 Wei	 et	 al (2010)	
also	found	that	HIV	kits	developed	using	individual	env 
gp41	 IDR	 peptides	 derived	 from	 respective	 subtypes	
failed	 to	detect	some	HIV	 infections	 by	other	subtypes.	
In	Zambia	and	Rwanda	a	study	by	Kilembe	et	al	(2012)	
found	that	a	new	rapid	antigen	and	antibody	test	could	
only	 detect	 less	 than	 2%	 of	 p24	 antigen	 positive	
samples.	It	is	also	known	that	the	main	challenge	in	the	
current	 global	 efforts	 to	 develop	 HIV	 vaccine	 is	 the	
extensive	 diversity	 of	 HIV	 env	 glycoprotein	 and	 one	 of	
the	 possible	 solutions	 that	 has	 been	 considered	 is	 to	
design	 region-specific	 vaccines	 to	 protect	 populations	
infected	by	a	specific	viral	strains	circulating	in	discrete	
geographic	areas	(Salemi,	2011).	
However,	 other	 studies	 have	 demonstrated	 that	 the	
performance	 of	 various	 HIV	 testing	 kits	 were	 not	
affected	by	the	prevailing	subtypes	of	HIV	infections	in	a	
specific	 region	 (Masciotra	 et	 al, 2000;	 Vallari	 et	 al,	
2010).	 A	 study	 by	 Masciotra	 et	 al	 (2000)	 established	
that	 Consensus envgp41	 from	 group	 M	 peptides	 was	
able	 to	 detect	 all	 130	 group	 M	 sera	 	 subtype	 A,	 21	
subtype	B,	13	subtype	B9,	20	subtype	C,	21	subtype	D,	
14	subtype	E,	25	subtype	F,	and	6	subtype	G)	resulting	
in	a	 test	sensitivity	of	100%.	Vallari	et	al (2010)	 noted	
that	 in	 spite	 of	 the	 high	 genetic	 divergence	 between	
HIV-1	 groups	 M	 and	 N,	 all	 group	 N	 infections	 were	
detected	using	five	commercial	HIV	immunoassays.		
Most	of	the	studies	on	the	effects	of	diversity	of	HIV	on	
their	 detection	 have	 been	 based	 on	
diagnostic/screening	 kits.	 However,	 when	 Wei	 et	 al 
(2010)	 were	 developing	 their	 HIV	 Incidence	 kit,	 they	
found	 that	 those	 kits	 that	 were	 developed	 using	
individual	 env gp41	 peptides	 derived	 from	 respective	
subtypes	 were	 unable	 to	 work	 well	 with	 samples	
containing	 other	 subtypes,	 and	 so	 they	 had	 to	 design	
multisubtype	 gp41	 recombinant	 antigen	 (rIDR-M)	 in	
order	to	improve	their	results		
Amidst	 the	 above	 controversies,	 this	 study	 was	
designed	 to	 develop	 immunoassays	 for	 HIV	 based	 on	
Consensus env	gp41	IDR	peptide	from	HIV	infections	in	
Kenya	 and	 to	 assess	 the	 effect	 this	 could	 have	 on	
detection	of	the	HIV	infections	and	determination	of	its	
Incidence.	
2. Materials and Methods 
2.1 Study design and Sampling 
The	 study	 design	 was	 the	 Laboratory-based	
Experimental	Design.		
A	 total	 of	 400	 samples	 (200	 HIV	 positive	 and	 200	 HIV	
negative)	 were	 picked	 from	 the	 four	 Regional	 Blood	
Transfusion	Centers	(uniformly	 spread	 among	the	 four	
centers	 over	 a	 period	 of	 three	 months).	 This	 was	 the	
minimum	 sample	 size	 that	 is	 recommended	 by	 World	
Health	 Organization	 (WHO)	 and	 Centers	 for	 Diseases	
Control	of	United	States	(CDC)	for	Evaluation	of	HIV	LFA	
and	 ELISA	 (WHO	 and	 CDC,	 2002).	 The	 sample	 size	
selected	 for	 sequencing	 was	 91	 based	 on	 the	
calculations	done	using	Fisher’s	formula	and	taking	into	
consideration	the	HIV	prevalence	of	6%	in	Kenya	then.	
2.2 PCR ampliﬁcation, sequencing, sequence 
analysis and peptide synthesis	
HIV	 viral	 RNA	 was	 extracted	 from	 91	 HIV	 positive	
samples	 using	 the	 QIAamp	 viral	 RNA	 kit	 (Qiagen,	
Valencia,	 Calif.)	 according	 to	 the	 manufacturer’s	
protocol.	 Primers	 were	 picked	 from	 the	 study	 by	
Dachraoui	 et	 al (2008)	 and	 synthesized	 by	 Bioneer	
Corporation	 (Seoul,	 South	 Korea).	 For	 reverse	
transcription	 (RT)	 and	 primary	 PCR,	 the	 primers	 used	
were	 GP40F1	 (forward;	
5′TCTTAGGAGCAGCAGGAAGCACTATGGG)	 and	 GP41R1	
(reverse;	 5′AACG	 ACAAAGGTGA	 GTATCCCTGCCTAA).	
For	 the	 nested	 PCR,	 the	 primers	 used	 were	 GP46F2	
(forward;	 5′ACAATTATTGTCTGGTATAGTGCAACAGCA)	
and	 GP47R2	 (reverse;	 5′TTAAACCTATCAA	 GCCTCC	
TACTATCATTA).	Three	to	10	μl	of	the	RNA	extract	were	
used	to	synthesize	cDNA	with	 primer	GP41R1	 (20	μM)	
and	 the	 GeneAmp	 RNA	 PCR	 kit	 (Perkin-Elmer	 Cetus,	
Norwalk,	Conn.)	 following	 the	manufacturer’s	 protocol.	
The	 20-μl	 cDNA	 reaction	 mixture	 was	 then	 added	 to	 a	
PCR	 mixture	 containing	 50	 μM	 GP40F1	 and	 30	 μM	
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GP41R1,	 1×	 GeneAmp	 PCR	 buffer	 II,	 1.25	 mM	 MgCl2,	
1.25	 mMdNTPs	 mix	 and	 2.5U	 of	 AmpliTaq	 DNA	
polymerase	(Perkin-Elmer	Cetus,	Foster	City,	Calif.)	and	
brought	to	a	final	volume	of	100	μl	with	sterile	distilled	
water.	 After	 initial	 denaturation	 at	 94	 °C	 for	 2	 min,	 35	
cycles	 of	 PCR	 were	 performed	 in	 the	 GeneAmp	 9600	
thermocycler	 (Perkin-Elmer	 Cetus,	 Norwalk,	 Conn.).	
Each	 cycle	 consisted	 of	 denaturation	 at	 94	 °C	 for	 30	 s,	
annealing	at	50	°C	for	30	s,	and	extension	at	72	°C	for	60	
s,	 with	 a	 final	 extension	 at	 72°C	 for	 5	 min.	 For	 nested	
PCR,	 5	 μl	 of	 the	 primary	 PCR	 product	 were	 added	 to	 a	
100-μl	PCR	mixture	containing	reagents	similar	to	those	
in	 the	 primary	 PCR,	 except	 that	 the	 primers	 were	
replaced	by	25	μM	each	GP46F2	and	GP47R2.	The	PCR	
mixture	 was	 subjected	 to	 35	 cycles	 under	 similar	
conditions	 as	 the	 primary	 PCR.	 After	 PCR,	 the	 nested	
PCR	 products	 were	 electrophoresed	 in	 1.5%	 agarose	
gels	 along	 with	 a	 100-bp	 ladder	 (Gibco,	 Grand	 Island,	
N.Y.)	 and	 visualized	 under	 UV	 light	 by	 ethidium	
bromide	staining.	The	Complementary	DNA	was	sent	to	
Macrogen	 Europe	 (Amsterdam,	 Netherlands)	 for	
sequencing	 using	 a	 big	 dye	 terminator	 v.	 3.1	 (PE)	 and	
the	same	primers	that	were	used	for	 initial	nested	PCR	
(GP46F2	 and	 GP47R2).	 The	 resultant	 sequences	 were	
aligned	 using	 CLUSTALW	 program	 within	 MEGA	 4	
Program	 (Tamura	 et	 al,	 2007).	 The	 prevailing	 HIV	
Consensus	 sequence	 was	 generated	 by	 use	 of	 the	
software	 “Advanced	 Consensus	 Maker”	 in	 the	 Los	
Alamos	 Database	 (Los	 Alamos,	 2009).	 The	 Global	
Consensus	 was	 obtained	 from	 the	 literature	 (Plantier,	
2009).	 The	 Consensus	 sequence	 of	 gp41	 IDR	 (Kenya)	
established	in	this	study	and	the	Global	Consensus	gp41	
IDR	 were	 then	 sent	 to	 LifeTein	 LLC	 (Hillsborough,	NJ)	
for	synthesis	of	env gp41	IDR	peptides.	
2.3 Development of ELISA using the synthetic 
peptide derived from the env gp41 region 
representing the Consensus sequence for HIV in 
Kenya 
The	 two	 synthetic	 HIV	 env gp41	 IDR	 peptides	 (Kenya:	
WGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTNVP
WNSSW	 and	 Global:	 WGIKQLQAR	
VLAVERYLKDQQLLGIWGCSGK	 LICTTAVPWNASW)	
were	 used	 to	 develop	 ELISA	 kits.	 Brieﬂy,	 polyvinyl	
plates	 (ImmulonII;	 Dynatech	 Laboratories,	 Inc.,	
Alexandria,	 Va.)	 were	 coated	 with	 5µg	 of	 synthetic	
peptide	 per	 ml	 (100	 ml/well)	 in	 0.01	 M	 carbonate	
buffer	 (pH	 9.6)	 and	 incubated	 overnight	 at	 4°C.The	
plates	 were	 washed	 6	 times	 with	 phosphate-buffered	
saline	(PBS)	containing	0.05%	Tween	20	(PBST);	excess	
reactive	 sites	 were	 blocked	 by	 the	 addition	 of	 5%	
Bovine	 Serum	 Albumin	 in	 PBST.	 This	 blocking	 buffer	
was	 arrived	 at	 through	 a	 series	 of	 optimization	 steps	
that	involved	various	types	of	blocking	buffers	and	their	
different	concentrations.	This	step	was	 followed	by	the	
addition	of	a	1:100	dilution	of	each	test	plasma	samples.	
The	 plates	 were	 incubated	 overnight	 at	 4°C.	 After	 six	
more	 washes,	 Fc-speciﬁc,	 HRP-conjugated	 goat	
antibody	to	human	immunoglobulin	G	(Sigma,	St.	Louis,	
Mo.)	was	added	and	the	plates	left	at	room	temperature	
for	 1	 hr.	 They	 were	 washed	 6	 times	 with	 PBST	 after	
which	100µl	of	3,	3’,	5,	5’-Tetramethylbenzidine	(TMB)	
/	 hydrogen	 peroxide	 substrate	 (MP	Biomedical,	 Santa	
Ana,	Calif.)	was	added	and	incubated	 for	30	minutes	 in	
the	dark.	To	stop	the	reaction,	100µl	of	1M	sulfuric	acid	
(Sigma,	 St.	 Louis,	 Mo.)	 was	 added	 and	 the	 Optical	
Density	(OD)	measured	at	450nm	with	Multiscan	ELISA	
Reader	(Thermo	Fisher	Scientific,	Waltham,	Mass.).	The	
cutoff	values	were	calculated	by	adding	0.1	to	the	mean	
optical	 densities	 plus	 3	 standard	 deviations	 of	 normal	
control	 sera	 in	 the	 assay.	 The	 p24-antibody	 and	 env	
gp36	 IDR	 peptides	 were	 incorporated	 and	 also	
optimized.	
2.4 Development of Lateral Flow Assay (LFA) using 
synthetic peptide derived from the gp41 region 
representing the Consensus sequence for HIV in 
Kenya		
The	key	step	in	the	process	of	preparation	LFA	was	the	
preparation	 viable	 colloidal	 gold	 conjugates	 (p24-
antibody,	 env	 gp41	 IDR	 peptides	 (Kenya	 and	 Global)	
and	 env	 gp36	 IDR	 peptide).	 These	 colloidal	 gold	
solutions	 were	 prepared	 by	 controlled	 reduction	 of	 a	
boiling	 solution	 of	 0.02%	 chloroauric	 acid	 with	 1%	
Sodium	 citrate	 according	 to	 the	 method	 described	 by	
Frens	(1973).	The	 LFA	was	 optimized	 through	a	 series	
of	experiments	as	described	by	Crowther	et	al (1995).	
2.5 Development of Incidence/Recency testing 
system 
The	 Two-well	 avidity	 index	 assays	 were	 conducted	
using	 ELISA	 wells	 coated	 with	 2.5	 µg	 HIV	 env	 gp41	
peptides	 rIDR-M,	 Consensus env	 gp41	 (Kenya)	 and	
Consensus env	gp41	(Global)	respectively	as	previously	
described	 by	 Wei	 et	 al (2010).	 Briefly,	 HIV	 env	 gp41	
peptides	 were	 reconstituted	 in	 0.1M	 PBS,	 applied	 on	
ELISA	 wells	 and	 incubated	 overnight.	 Plates	 were	
washed	 with	 PBS	 containing	 0.1%	 Tween-20	 and	
blocked	with	5%	nonfat	dry	milk	powder	in	PBST	(milk	
buffer).	A	100	ml	aliquot	of	diluted	sample	in	ratio	of	1	
to	400	with	milk	buffer	was	added	to	the	two	wells	and	
incubated	for	1hr	at	37	°C.	The	plate	was	then	washed	4	
times	with	300	µl	well	of	PBST.	One	well	was	incubated	
with	 dissociation	 buffer	 pH	 3.0	 while	 the	 second	 well	
(control)	 was	 incubated	 with	 wash	 buffer	 at	 37	 °C	 for	
15	min.	The	plate	was	then	washed	4	times	with	300ml	
of	 PBST.	 One	 hundred	 microliters	 of	 goat-antihuman	
IgG	peroxidase,	diluted	1:5000	in	milk	buffer	was	added	
and	incubated	at	37	°C	for	30	min,	followed	by	4	washes	
with	 300	 µl	 of	 PBST.	 One	 hundred	 microliters	 of	 TMB	
was	added	and	incubated	at	25	°C	for	15	min.	The	color	
development	 was	 stopped	 by	 the	 addition	 of	 100	 µl	 of	
1N	Sulphuric	acid	 to	each	 well	and	the	OD	was	read	at	
450	nm.	The	Avidity	Index	(AI)	was	calculated	as	a	ratio	
of	 OD	 of	 the	 treated	 well	 divided	 by	 the	 OD	 of	 the	
control	well,	expressed	as	a	percent,	with	a	cut-off	score	
of	above	80%	being	graded	as	recent	(an	 overall	mean	
duration	of	recency	of	141	days	according	to	the	study	
by	Wei	et	al, 2010)	
2.6 Data analysis 
The	 bioinformatics	 data	 in	 this	 study	 was	 analyzed	
using	 Los	 Alamos,	 NCBI	 and	 MEGA	 bioinformatics	
suites.	 Correlation	 of	 coefficient,	 p-values,	 levels	
significance,	 One-way	 ANOVA	 and	 F-Test	 values	 of	
various	data	were	also	calculated	as	applicable.		
2.7 Ethical Considerations 
The	 study	 was	 approved	 by	 KEMRI	 Ethical	 Review	
Committee	(Protocol no. 2170	dated	April	2012).	
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Table 1:	The	frequency	of	various	types	of	amino	acid	substitutions	in	HIV	gp41-IDR	peptide	(Kenya)	
Amino acid  and 
position 
Frequency  
Unique or common 
substitution(s) 
Amino acid  
and position 
Frequency  
Unique or common 
substitution(s) 
A101→S	 68	 Not	unique	 Q79→R	 1	 Not	unique	
K77→R	 31	 Not	unique	 S88→A	 1	 Not	unique	
A96→	N	 50	 Not	unique	 K90→V	 1	 Unique	
I84→L	 17	 Not	unique	 A101→Y	 1	 Unique	
A96→	T	 16	 Not	unique	 G83→A	 1	 Unique	
V72→L	 15	 Not	unique	 I84→F	 1	 Unique	
T94→P	 12	 Not	unique	 R99→W	 1	 Not	unique	
A96→T	 9	 Not	unique	 V77→I	 1	 Not	unique	
R68→S	 8	 Unique	 I84→V	 1	 Unique	
L91→H	 7	 Not	unique	 C87→S	 1	 Unique	
V69→I	 7	 Not	unique	 Q66→K	 1	 Unique	
A71→G	 5	 Unique	 Q66→H	 1	 Unique	
L91→I	 10	 Not	unique	 Q66→R	 1	 Not	unique	
K90→R	 5	 Not	unique	 R74→S	 1	 Not	unique	
A101→T	 5	 Not	unique	 L91→R	 1	 Unique	
K77→Q	 4	 Not	unique	 P98→R	 1	 Unique	
T94→S	 4	 Unique	 A101→V	 1	 Unique	
K77→V	 3	 Unique	 A67→	T	 1	 Not	unique	
V72→I	 3	 Not	unique	 R68→E	 1	 Unique	
V69→I	 7	 Not	unique	 Q66→	P	 1	 Not	unique	
A71→G	 5	 Unique	 A96→	S	 1	 Not	unique	
K90→R	 5	 Not	unique	 R74→A	 1	 Not	unique	
A101→T	 5	 Not	unique	 K77→T	 1	 Not	unique	
K77→Q	 4	 Not	unique	 Q80→R	 1	 Not	unique	
T94→S	 4	 Unique	 L91→P	 1	 Unique	
K77→V	 3	 Unique	 L70→Q	 1	 Unique	
V72→I	 3	 Not	unique	 G83→R	 1	 Not	unique	
A96→F	 3	 Not	unique	 R68→K	 1	 Not	unique	
A67→T	 3	 Not	unique	 Q79→H	 1	 Unique	
I62→V	 2	 Unique	 C93→S	 1	 Unique	
L70→	Q	 2	 Unique	 L81→P	 1	 Unique	
C87→L	 2	 Unique	 L82→P	 1	 Not	unique	
R74→K	 2	 Not	unique	 K77→G	 1	 Not	unique	
R74→G	 2	 Not	unique	 V69→L	 1	 Not	unique	
L81→I	 2	 Not	unique	 Y75→F	 1	 Not	unique	
K77→E	 1	 Not	unique	 T94→A	 1	 Not	unique	
D78→H	 1	 Unique	 V69→M	 1	 Unique	
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Figure 1:		Shannon-Two	Entropy	of	alignments	of	91	HIV	gp41	IDR	peptide	sequences	
	
3.  Results 
3.1 Consensus peptide sequence for HIV gp41 IDR 
(Kenya)	
This	 study	 established	 that	 the	 Consensus	 peptide	
sequence	 for	 HIV	 env gp41	 IDR	 (Kenya)	 was	
WGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTNVP
WNSSW.	 The	 study	 found	 only	 two	 amino	 acids	
differences	 between	 HIV	 Consensus env gp41-IDR	
peptide	 (Kenya)	 and	 HIV	 Consensus env gp41-IDR	
peptide	 (Global)	 where	 A96→N	 and	 A101→S	 giving	 a	
similarity	 of	 95.3%	 between	 the	 two	 sequences.	 There	
was	100%	sequence	similarity	in	the	key	sub-regions	of	
IDR	 of	 env gp41:	 the	 CTL	 epitope	 (aa	 71	 to	 82;	
AVERYLKDQQLL)	 and	 the	 Cysteine	 Loop	 (aa	 87	 to	 93;	
CSGKLIC).When	 BLAST	 analysis	 of	 the	 HIV	 Consensus 
env gp41-IDR	 peptide	 (Kenya)	 was	 carried	 out	 at	 the	
NCBI	 database,	 more	 than	 200	 sequences	 with	 100%	
sequence	 similarity	 were	 found	 implying	 that	 this	
Consensus	 sequence	 was	 not	 unique.	 However,	 when	
individual	 sequences	 were	 analyzed,	 74	 different	
substitutions	 (in	 comparison	 with	 HXB2	 sequence)	
were	 noted	 among	 the	 env gp41	 IDR	 (Kenya),	 out	 of	
which	29	(39.2%)	were	unique	(Table 1).	
When	Shannon-Two	Entropy	of	alignment	of	91	HIV	env 
gp41	IDR	peptide	sequences	obtained	in	this	study	was	
determined	using	Los	Alamos	“Entropy”	software	(Foley	
et	 al,	 2013)	 with	 HXB2	 gp41	 IDR	 peptide	 as	 a	
background	 sequence,	 position	 77R	 was	 the	 most	
variable	 position	 with	 the	 Shannon	 Entropy	 value	 of	
1.266	 followed	 by	 N96	 (1.217),	 74R	 (0.813),	 94T	
(0.755),	91L	(0.742),	84	(0.686)	and	101S	(0.629).	Sixty	
seven	 point	 four	 percent	 (67.4%)	 of	 the	 amino	 acid	
positions	 were	 conserved	 with	 the	 Entropy	 value	 of	
below	 0.25	 (baseline	 Entropy)	 with	 positions	 60W	
(entropy	value	 of	0.06)	and	61G	(entropy	value	of	 0.0)	
being	the	most	conserved	(Figure 1).	
3.2 HIV incidence in Kenya 
The	 Standard	 ELISA	 procedure	 carried	 out	 using	 wells	
coated	 with	 rIDR-M	 peptide	 gave	 the	 HIV	 Incidence	 of	
31.9%	while	the	tests	that	were	carried	out	using	wells	
coated	 with	 HIV	 Consensus env	 gp41	 IDR	 (Global)	 and	
Consensus env	gp41	IDR	(Kenya)	peptides	gave	the	HIV	
Incidences	 of	 76.9%	 and	 41.8%	 respectively	 using	 the	
Avidity	 Index	(AI)	cut	off	point	of	80%	(Figure 2).	The	
results	 of	 the	 tests	 that	 were	 carried	 out	 using	 wells	
coated	 with	 Consensus env	 gp41	 IDR	 (Kenya)	 peptide	
were	closer	to	the	Standard	than	those	from	Consensus 
env	gp41	IDR	(Global)	peptide.	
Figure 2: HIV	 Incidence	 using	 wells	 coated	 with	
Consensus	 env	 gp41	 IDR	 Kenya),	 Consensus	 env	 gp41	
IDR	 (Global)	 and	 the	 Standard	 (r-IDR-M	 peptide)	
respectively	
	
3.3 The comparison of the performance of Control 
wells (without the dissociation of immune-
complex)during the determination of HIV Incidence  
The	 optical	 densities	 of	 wells	 which	 were	 treated	 with	
PBS	 (control	 wells)	 in	 ELISA	 system	 coated	 with	 three	
peptides	{rIDR-M,	Consensus env	gp41	IDR	(Kenya)	and	
Consensus env	gp41	IDR	(Global)	respectively}	showed	
close	correlation	of	the	performance	of	the	three	ELISA	
systems	 (Figure 3).	 	 The	 correlation	 between	 the	
Control	 ELISA	 system	 of	 Consensus env	 gp41	 IDR	
(Kenya)	 and	 Consensus env	 gp41	 IDR	 (Global)	 was	 the	
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closest	(R	=	0.9823,	P-Value	<	0.00001	and	significant	at	
p	 <	 0.05).	 The	 correlation	 between	 the	 Control	 ELISA	
system	 of	 Consensus env	 gp41	 IDR	 (Kenya)	 and	
Consensus env	gp41	IDR	(rIDR-M)	was	the	(R	=	0.7206,	
P-Value	<	0.00001	and	significant	at	p	<	0.05)	one	which	
was	closer	than	that	of	Consensus env	gp41	IDR	(Global)	
and	Consensus env	gp41	IDR	(rIDR-M)	(R	=	0.	0.7086,	P-
Value	<	0.00001	and	significant	at	p	<	0.05).	When	One-
way	 ANOVA	 was	 computed	 with	 results	 from	 rIDR	 as	
dependent	variables	the	F-Test	value	for	Control	ELISA	
system	 of	 Consensus env	 gp41	 IDR	 (Kenya)	 was	 2.299	
(significant	 value	of	0.103)	 while	 that	 of	Control	 ELISA	
system	 of	 Consensus env	 gp41	 IDR	 (Global)	 was	 2.015	
(significant	value	of	0.144)	implying	that	the	difference	
among	the	three	ELISA	systems	was	not	significant	at	p-
value	of	0.05).	
3.4 Comparison of performance of wells treated 
with a dissociation buffer (Citrate buffer at pH 3) 
during determination of HIV Incidence 
The	 optical	 densities	 of	 wells	 which	 were	 treated	 with	
dissociation	buffer	(Citrate	buffer	pH	3)	in	ELISA	system	
coated	 with	 three	 peptides	 respectively	 rIDR-M,	
Consensus env	 gp41	 IDR	 (Kenya)	 and	 Consensus env	
gp41	 IDR	 (Global)	 showed	 an	 existence	 correlation	 of	
the	performance	of	the	three	ELISA	systems	(Figure 4).  
The	correlation	between	the	ELISA	system	of	Consensus 
env	 gp41	 IDR	 (Kenya)	 and	 Consensus env	 gp41	 IDR	
(Global)	 after	 using	 Dissociation	 buffer	 was	 the	 closest	
(R	 =	 0.9739,	 P-Value	 <	 0.00001	 and	 significant	 at	 p	 <	
0.05).	 The	 correlation	 between	 the	 Control	 ELISA	
system	 of	 Consensus env	 gp41	 IDR	 (Kenya)	 and	
Consensus env	gp41	IDR	(rIDR-M)	was	the	(R	=	0.8044,	
P-Value	 <	 0.00001	 and	 significant	 at	 p	 <	 0.05)	 which	
was	closer	than	that	of	Consensus env	gp41	IDR	(Global)	
and	Consensus env	gp41	IDR	(rIDR-M)	was	the	(0.7588,	
P-Value	 <	 0.00001	 and	 significant	 at	 p	 <	 0.05).	 When	
One-way	ANOVA	was	computed	with	results	from	rIDR	
as	 dependent	 variables	 the	 F-Test	 value	 for	 Consensus 
env	 gp41	 IDR	 (Kenya)	 was	 4.550	 (significant	 value	 of	
0.006)	while	that	of	Control	ELISA	system	of	Consensus 
env	 gp41	 IDR	 (Global)	 was	 6.677	 (significant	 value	 of	
0..001)	 implying	 that	 the	 significant	 difference	 among	
the	three	ELISA	systems	at	p-value	of	0.05).		
This	 computation	 also	 show	 that	 Consensus env	 gp41	
IDR	 (Global)	 deviated	 more	 from	 the	 Standard	 than	
Consensus env	 gp41	 IDR	 (Kenya)	 a	 fact	 that	 is	 also	
demonstrated	in	Figure 2.	
	
Figure 3:.Comparison	 of	 the	 HIV	 incidence	 test	 results	 of	 ELISA	 system	 coated	 with	 three	 peptides:	 rIDR-M,	
Consensus env	gp41	IDR	(Kenya)	and	Consensus env	gp41	IDR	(Global)	respectively.	
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Figure 4: Relationship	between	the	performances	of	samples	treated	with	dissociation	buffer	(Citrate	buffer	pH	3)	in	
ELISA	system	coated	with	three	peptides	respectively:	rIDR-M,	Consensus env	gp41	IDR	(Kenya)	and	Consensus env	
gp41	IDR	(Global)	
	 	 	 	
Figure 5:	Relationship	between	the	Avidity	 indices	 in	 ELISA	system	coated	with	 three	peptides:	rIDR-M,	Consensus 
env	gp41	IDR	(Kenya)	and	Consensus env	gp41	IDR	(Global)respectively	
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Table 2:		Performance	of	various	Rapid	test	kits	in	respect	to	Consensus	status	with	LFAs	
HIV Rapid Test Kit D-SN (95% CI) D-SP (95% CI) PPV (95% CI) NPV (95% CI) 
Determine™	HIV-1/2		 100	(97.4-100.0)	 96.8	(83.2	-	99.5)	 99.3	(96.1	-	99.9)	 100	(88.3-100.0)	
KHB	Colloidal	Gold	 100	(97.4-100.0)	 100	(88.7-100.0)	 100	(97.4-100.0)	 100	(88.7	-	100.0)	
Uni-Gold™	HIV	test		 96.4	(91.8	-	98.8)	 100.0	(88.7-100.0)	 100.0	(97.3-100.0)	 86.1	(70.5-95.3)	
First	Response™	 100	(97.4-100.0)	 96.8	(83.2	-	99.5)	 99.3	(96.1-	99.9)	 100	(88.3	-	100.0)	
Aware™	HIV-1/2	BSP	 99.3	(96.0	-	99.9)	 100.0	(88.7-100.0)	 100.0	(97.3	-	00.0)	 96.9	(83.7-99.5)	
In-House	HIV	1/2		LFA	 99.3	(96.0	-	99.9)	 100.0	(88.7-100.0)	 100.0	(97.3	-	00.0)	 96.9	(83.7-99.5)	
*D-SN   Diagnostic Sensitivity; D-SP   Diagnostic	specificity;		PPV		Positive	Predictive	value;	NPV	Negative	Predictive	value	
	
Table 3:	Performance	of	ELISA	kits	developed	using	Consensus env	gp41	IDR	(Kenya	&	Global)	and	Vironostika™	Uni-
Form	II	Ag/Ab	ELISA	
ELISA D-SN (95% CI) D-SP (95% CI) PPV (95% CI) NPV (95% CI) 
Consensus env	gp41	IDR	
(Kenya)	
97.24	(93.1	-	99.2)	 100	(86.3-100.0)	 100	(97.4-100.0)	 86.2	(68.4	–	96.1)	
Consensus env	gp41	IDR	
(Global)	
97.24	(93.1	-	99.2)	 100	(86.3-100.0)	 100	(97.4-100.0)	 86.2	(68.4	–	96.1)	
	
	
  Figure 6:	The	relative	Analytical	Sensitivity	of	HIV	LFAs	in	Kenya	using	panels	that	was	prepared	in-house	
3.5 Comparison of Avidity indices during 
determination of HIV Incidence  
The	Avidity	 Index	(AI)	of	wells	 in	ELISA	system	coated	
with	 the	 three	 peptides	 rIDR-M,	 Consensus env	 gp41	
IDR	 (Kenya)	 and	 Consensus env	 gp41	 IDR	
(Global)respectively	showed	an	existence	of	correlation	
of	the	performance	of	the	three	ELISA	systems	(Figure 
5). The	 correlation	 between	 the	 ELISA	 system	 of	
Consensus env	 gp41	 IDR	 (Kenya)	 and	 Consensus env	
gp41	 IDR	 (Global)	 was	 strong	 (R	 =	 0.8349,	 P-Value	 <	
0.00001	 and	 significant	 at	 p	 <	 0.05).	 The	 correlation	
between	 the	 ELISA	 system	 of	 Consensus env	 gp41	 IDR	
(Kenya)	 and	 Consensus env	 gp41	 IDR	 (rIDR-M)	 was	
weak	(R	=	0.4535,	P-Value	<	0.00001	and	significant	at	
p	 <	 0.05)	 which	 was	 closer	 than	 that	 of	 Consensus env	
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gp41	IDR	(Global)	and	env	gp41	IDR	(rIDR-M)	was	weak	
(R	 =	 0.3546,	 P-Value	 <	 0.000563	 and	 significant	 at	 p	 <	
0.05).	 	 When	 One-Sample	 T-Test	 was	 computed	 it	 was	
found	 that	 the	 T-Statistic	 values	 were	 23.980,	 27.885	
and	 28.041	 for	 Consensus env	 gp41	 IDR	 (Global),	 env	
gp41	 IDR	 (rIDR-M)	 and	 Consensus env	 gp41	 IDR	
(Kenya)	 respectively	 indicating	 a	 greater	 deviation	 of	
the	 Avidity	 index	 of	 the	 Consensus env	 gp41	 IDR	
(Global)	from	the	Standard	env	gp41	IDR	(rIDR-M)	than	
with	Consensus env	gp41	IDR	(Kenya).	
3.6 Evaluation of the developed immunoassays 
The	LFA	that	was	developed	using	Consensus env	gp41	
IDR	 (Kenya)	 showed	 a	 Diagnostic	 Sensitivity	 (D-SN)	 of	
99.3	(95%	CI:	96.0	-	99.9)	and	Diagnostic	Specificity	(D-
SP)	of	100%	(95%	CI:	88.7-100.0)	which	was	similar	to	
Aware™	HIV-1/2	BSP	and	better	performance	than	Uni-
Gold™	HIV	test	(Table 2).	
3.7 Analytical Sensitivity of the developed 
immunoassays 
Determine™	 HIV-1/2	 showed	 the	 highest	 sensitivity	 in	
comparison	 with	 other	 HIV	 LFAs	 (Figure 6).	 The	
performance	of	KHB	Colloidal	Gold	and	First	Response™	
1-2.0	 were	comparable	 (13	 and	 11	 for	 panel	 P-A-15;	 9	
and	11	for	panel	P-B-15	and	12	and	12	for	P-C-15).	Uni-
Gold™	 HIV	 showed	 the	 lowest	 Analytical	 Sensitivity	
(with	detection	limit	at	9,	5	and	8	dilutions	of	the	three	
HIV	panels	respectively).	
4. Discussion 
This	study	established	the	Consensus	peptide	sequence	
for	 HIV	 env	 gp41	 IDR	 (Kenya)	 to	 be:	
WGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTNVP
WNSSW.	When	BLAST	analyses	of	this	peptide	sequence	
were	carried	 out	at	 the	NCBI	 data	 base	 more	 than	200	
sequences	 with	 100%	 sequence	 identity	 were	 found	
implying	 that	 this	 consensus	 sequence	 is	 not	 a	 unique	
Consensus	sequence.	However,	the	study	found	that	this	
Consensus	peptide	differed	from	the	HIV	Consensus env	
gp41-IDR	 peptide	 (Global)	 (Masciotra	 et	 al,	 2000)	 by	
two	 amino	 acids	 where	 A96→N	 and	 A101→S	 giving	 a	
similarity	 of	 95.3%.	 Further	 examination	 of	 each	
sequence	yielded	74	substitutions	of	which	29	(39.2%)	
were	 unique	 (aKimotho	 et	 al,	 2015).	 Sixty	 seven	 point	
four	 percent	 (67.4%)	 of	 the	 amino	 acid	 positions	 were	
conserved	 with	 the	 Entropy	 value	 of	 below	 0.25	 with	
the	most	conserved	positions	being	positions	 60W	and	
61G.	 The	 study	 also	 found	 that	 the	 HIV	 sub-type	
distribution	 among	 the	 blood	 donors	 in	 Kenya	 was	 A1	
(76.9%),	 C	 (6.6%),	 D	 (14.3%)	 and	 CRF	
A2.CY.94CY017_41	 (2.2%),	 which	 was	 not	 significantly	
different	 from	 the	 results	 that	 are	 recorded	 in	 Los	
Alamos	 data	 base	 for	 HIV	 (P-Value	 =	 1;	 p	 <	 0.05)	 (Los	
Alamos,	2015).	
The	 HIV	 Incidence	 (or	 Recency)	 testing	 conducted	 in	
this	 study	 using	 the	 Two-Well	 Avidity-Based	 assays	
(Wei	et	al, 2010)	found	that	31.9%	of	91	samples	tested	
using	 ELISA	 wells	 coated	 with	 Consensus env	 gp41	
rIDR-M	 peptide	 (as	 the	 standard)	 were	 recent.	 When	
the	 same	 samples	 were	 tested	 for	 recency	 using	 wells	
coated	 with	 Consensus env	 gp41	 IDR	 (Global)	 and	
Consensus env	 gp41	 IDR	 (Kenya)	 peptides	 the	 HIV	
Incidence	 was	 found	 to	 be	 76.9%	 and	 41.8%	
respectively.	 Previous	 studies	 in	 Kenya	 reported	 the	
rate	 of	 recent	 HIV	 infection	 of	 11%	 among	 the	 HIV	
seropositive	 individuals	 (WHO,	 2009),	 using	 the	 BED	
CEIA	testing	protocol,	with	males	aged	25-35	years	old	
showing	the	highest	percentage	of	recent	HIV	infection	
at	 47%.	 The	 study	 also	 found	 that	 the	 age	 group	 with	
the	 largest	 discrepancy	 in	 recent	 infection	 between	
males	 and	 females	 was	 the	 15-24	 year	 old	 age	 group	
(36%	 in	 females	 vs.	 13%	 in	 males)	 (WHO/UNAIDS,	
2013).	 According	 to	 NASCOP	 (2015)	 the	 current	 HIV	
Incidence	 in	 Kenya	 is	 0.44%	 of	 the	 general	 population	
(or	 7.3%	 of	 the	 HIV	 positive	 cases).	 In	 Kenya,	 about	
70%	of	blood	donors	are	aged	between	15-19	years	old	
while	 30%	 are	 about	 20-64	 years	 old.	 This	 may	 partly	
explain	 the	 HIV	 Incidence	 of	 31.9%	 obtained	 in	 this	
study.	 The	 False	 Recency	 Rate	 (FRR)	 is	 reported	 to	 be	
about	 5%	 due	 to	 presence	 of	 Elite	 controllers	
(individuals	 who	 naturally	 maintain	 low	 or	
undetectable	 HIV	 RNA	 levels	 and	 have	 low	 antibody	
responses)	 (UNAIDS,	 2013)hence	 after	 adjustment	 the	
HIV	 Incidence	 is	 26.9%.	 The	 study	 established	 that	
although	 the	 three	 peptides	 (Consensus env	 gp41	 IDR	
(Kenya),	 Consensus env	 gp41	 IDR	 (Global),	 env	 gp41	
IDR	 (rIDR-M),	 showed	 insignificant	 difference	 when	
they	 were	 used	 to	 develop	 HIV	 detection	 ELISA	 they	
displayed	significant	difference	when	they	were	used	to	
develop	HIV	incidence	kits.	These	results	imply	that	the	
three	 peptides	 that	 were	 used	 to	 run	 the	 three	 ELISA	
are	 likely	 to	 have	 different	 Immune-Complex	
Dissociation	kinetics	in	the	presence	of	the	dissociation	
buffer.	
When	 the	 developed	 kits	 were	 evaluated	 it	 was	 found	
that	 there	 was	 no	 significant	 difference	 between	 the	
performance	 of	 the	 HIV	 ELISA	 Testing	 kit	 that	 was	
developed	 with	 Consensus env gp41-IDR	 peptide	
(Kenya)	and	that	which	was	developed	using	Consensus	
gp41-IDR	 peptide	 (Global)	 with	 both	 having	 a	
Diagnostic	sensitivity	of	97.2%.	This	finding	seems	to	be	
in	 favour	 of	 findings	 by	 Masciotra	 et	 al. (2000)	 who	
established	 that	 Consensus	 gp41-IDR	 from	 group	 M	
peptides	 (WGIKQLQARVLAVERYLKDQQLLGIWGCSGKL	
ICTTAVPWNASW)	 was	 able	 to	 detect	 all	 130	 group	 M	
sera	 (10	 subtype	 A,	 21	 subtype	 B,	 13	 subtype	 B9,	 20	
subtype	 C,	 21	 subtype	 D,	 14	 subtype	 E,	 25	 subtype	 F,	
and	 6	 subtype	 G).	 The	 study	 also	 agrees	 with	 the	
findings	 by	Vallari	et	 al (2010)	who	 noted	 that	 despite	
the	 high	 genetic	 divergence	 between	 HIV-1	 groups	 M	
and	 N,	 all	 group	 N	 infections	 were	 detected	 using	 five	
commercial	 HIV	 immunoassays	 (Vallari	 et	 al,	 2010).	
Dorn	 et	 al	 (2000)	 noted	 that	 substitutions	 observed	
within	 the	 IDR	 of	 gp41	 of	 HIV-1group	 M	 subtypes	 do	
not	 affect	 antibody	 recognition	 and	 that	 all	 HIV-1-
seropositive	 specimens	 containing	 the	 observed	
substitutions	 reacted	 with	 the	 FDA-licensed	 ELISA	 kits	
regardless	of	viral	genotype	and	geographic	origin.	This	
may	be	explained	from	the	finding	in	this	study	that	the	
three	 Consensus	 peptides	 had	 100%	 sequence	
similarity	in	the	key	sub-regions	of	IDR	of	gp41:	the	CTL	
epitope	(aa	71	to	82;	AVERYLKDQQLL)	and	the	Cysteine	
Loop	 epitope	 (aa	 87	 to	 93;	 CSGKLIC).	 During	 the	
evaluation	process	it	was	established	that	the	Analytical	
Sensitivity	 of	 Determine™	 HIV-1/2	 Combo	 Ag/Ab	 LFA	
(Abbott	 Diagnostic	 Division,	 Hoofddorp,	 The	
Netherlands)	 in	 respect	 to	 testing	 for	 HIV	 p24	 antigen	
was	 	 the	 same	 as	 that	 of	 Vironostika™	 Uni-Form	 II	
Ag/Ab	 ELISA	 (bioMérieux,	 Marcy-l'Etoile,	 France).	 Also	
during	the	process	of	evaluation	it	was	established	that	
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the	 overall	 D-SN	 of	 using	 LFAs	 in	 HIV	 testing	 in	 Kenya	
was	 found	 to	 96.0%	 (95%	 CI:	 92.3-98.3%).	 Mine	 et	 al	
(2015)	 found	 a	 D-SN	 and	 D-SP	 of	 98.2%	 and	 100%	
respectively	for	KHB Colloidal Gold	against	Vironostika™	
Uni-Form	 II	 Ag/Ab	 ELISA	 as	 Gold	 Standard	 and	 D-SN	
and	 D-SP	 of	 98.2%	 and	 98.1%	 respectively	 for	 Uni-
Gold™	 HIV	 test	 against	 the	 same	 ELISA	 kit.	 However,	
Fabiani	 et	 al (2005)	 found	 a	 low	 sensitivity	 of	 the	 HIV	
Testing	Algorithm	using	Rapid	Tests	of	90.6%	(95%	CI:	
78.6	-96.5)	when	compared	with	an	ELISA	system.	
The	 evaluation	 of	 the	 developed	 LFA	 kits	 was	 done	
using	plasma	samples	thus	restricting	 the	future	use	of	
these	 kits	 to	 testing	 of	 HIV	 in	 the	 plasma	 matrix	 only.	
This	 was	 due	 to	 the	 limitations	 of	 funds.	 It	 is	
recommended	 that	 the	 LFA	 developed	 in	 this	 study	 be	
evaluated	with	whole	blood	samples	in	future.	
In	 conclusion	 this	 study	 developed	 diagnostic	
immunoassays	whose	performance	was	not	affected	by	
use	 of	 Consensus env gp41-IDR	 peptides	 (Kenya)	
andenv gp41-IDR	peptides	(Global).	However,	the	study	
demonstrated	 that	 Consensus env gp41-IDR	 peptide	
(Kenya)	could	be	more	suitable	for	development	of	HIV	
Incidence	 assays	 in	 Kenya	 than	 env gp41-IDR	 peptide	
(Global).	
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